Novo Nordisk ready to go toe to toe with Ascendis

Should Novo Nordisk end up in direct competition with Ascendis Pharma on the growth hormone market, the Danish pharmaceutical giant has an arsenal ready, including a network of doctors and payers, says CEO Lars Fruergaard Jørgensen.

Lars Fruergaard Jørgensen, CEO at Novo Nordisk | Photo: Stine Bidstrup/ERH

The stage is being set for a battle of the Danes, with pharmaceutical giant Novo Nordisk in one corner and biotech firm Ascendis Pharma, which is on the upswing, in the other.

Soon, both firms will go head to head on the market for growth hormone deficiency (GHD) treatments for children, as Novo Nordisk plans to submit its once-weekly growth hormone, Sogroya, for registration in the first half of 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs